Drug
Allo 501
Allo 501: highest development phase Phase 1, developed by Allogene Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Allogene Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALLO-501 NCT03939026 | Phase 1 | Relapsed/Refractory Large B Cell Lymphoma |
Latest
No recent events.
Follow Allo 501 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.